skip to content
Dovepress - Open Access to Scientific and Medical Research
View our mobile site

8838

Azithromycin in DuraSite® for the treatment of blepharitis

Review

(3377) Views  (1194) Full article downloads

Authors: Jodi Luchs

Published Date June 2010 Volume 2010:4 Pages 681 - 688
DOI: http://dx.doi.org/10.2147/OPTH.S6370

Jodi Luchs

Department of Ophthalmology and Visual Sciences, Albert Einstein College of Medicine, Bronx, NY, USA

Abstract: Blepharitis is a common inflammatory disease of the eyelid. Posterior blepharitis affects the posterior lamella of the eyelid and involves inflammation of the meibomian glands, whereas anterior blepharitis affects the anterior lamella of the eyelid and the eyelashes; either version can be inflammatory or infectious in nature. Each of these conditions can incite or propagate the other; anterior blepharitis, if not treated, can lead to meibomian gland disease, and vice versa. Blepharitis is typically chronic, and can be associated with a variety of systemic diseases such as dermatitis, as well as ocular diseases such as dry eye, conjunctivitis, or keratitis. The standard treatment regimen historically consists of lid hygiene with warm compresses and eyelid scrubs, although these treatment modalities may have limited efficacy for many patients, especially those with more severe disease. Adjunctive treatment includes systemic and topical antibiotics, topical corticosteroids, and tear replacement therapy. Topical antibiotics are recommended to decrease the bacterial load, and topical corticosteroids may help in cases of severe inflammation. Azithromycin ophthalmic solution 1% in DuraSite® (AzaSite®; Inspire Pharmaceuticals, Durham, North Carolina, USA) has been proposed as a novel treatment for posterior blepharitis, based on its well-known anti-infective profile, its antiinflammatory properties, its excellent tissue penetration, and its regulatory approval for the treatment of bacterial conjunctivitis. This review focuses on an off-label indication for topical azithromycin 1% in DuraSite for the treatment of blepharitis.

Keywords: lid margin disease, meibomian gland disease








Readers of this article also read:

Candida albicans keratitis modified by steroid application
Topical ganciclovir in the treatment of acute herpetic keratitis
Optic disc measurements using the Heidelberg Retina Tomograph in amblyopia
Evaluation of alcaftadine 0.25% ophthalmic solution in acute allergic conjunctivitis at 15 minutes and 16 hours after instillation versus placebo and olopatadine 0.1%
Influence of ischemia on visual function in patients with branch retinal vein occlusion and macular edema
Evaluation of olopatadine 0.2% in the complete prevention of ocular itching in the conjunctival allergen challenge model
High-resolution wide-field imaging of perfused capillaries without the use of contrast agent
Cumulative clinical experience from over a decade of use of levofloxacin in community-acquired pneumonia: critical appraisal and role in therapy
Significant correlations between optic nerve head microcirculation and visual field defects and nerve fiber layer loss in glaucoma patients with myopic glaucomatous disk
Comparative efficacy of topical tetracaine solution versus lidocaine gel in cataract surgery